AtheroGenics AGI-1067 Development In Diabetes Takes Step Forward
This article was originally published in The Pink Sheet Daily
Positive diabetes data, coupled with earlier cardiovascular outcomes, could facilitate approval of AGI-1067 in era of cautious FDA, firm says.
You may also be interested in...
The biggest pharmaceutical companies are least affected by the current credit crisis due to their strong balance sheets and hefty piles of cash, yet even they are finding debt is more expensive and harder to obtain. Big biotechs also have billions of dollars in cash and marketable securities. Smaller, development stage companies, however, are more fragile because their existence depends on their ability to raise money to fund their R&D.Specialty pharma falls in between big pharma and biotech: the group is vulnerable, but not as much as biotech. The lack of access to capital makes doing deals tougher and more expensive.
Endocrinologic and Metabolic Drugs Advisory Committee asks the agency to eliminate a degree of risk for all candidates, even if no safety signal emerges from the clinical program.
Atherogenics will begin looking for a new partner for the former atherosclerosis treatment, firm tells “The Pink Sheet” DAILY.